{"id":29455,"date":"2023-05-09T09:27:49","date_gmt":"2023-05-09T09:27:49","guid":{"rendered":"https:\/\/celonpharma.com\/faind-2-0\/"},"modified":"2023-05-09T12:13:39","modified_gmt":"2023-05-09T12:13:39","slug":"faind-2-0","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/faind-2-0\/","title":{"rendered":"FAIND 2.0"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"908\" height=\"93\" src=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/02\/pasek-rna.jpg\" alt=\"\" class=\"wp-image-22996\" srcset=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/02\/pasek-rna.jpg 908w, https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/02\/pasek-rna-300x31.jpg 300w, https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/02\/pasek-rna-768x79.jpg 768w\" sizes=\"auto, (max-width: 908px) 100vw, 908px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Co-financing from the state budget from the Medical Research Agency<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Project: <strong>FGF1 analogue: a new therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Agreement No.: 2022\/ABM\/05\/00005<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The aim of the project &#8220;FGF1 analogue: a new therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases&#8221; is to bring to the market a new product based on protein therapy targeting so-called metabolic syndrome: non-alcoholic fatty liver disease (NAFLD), obesity, hypertriglyceridemia, hypercholesterolemia and hyperglycemia. The indicated therapeutic areas are important targets for modern therapies, since the incidence of the metabolic syndrome ranges from 20 to 25% in the adult population and from 0 to 19.2% in children; but can be as high as almost 80% in people with type 2 diabetes. A combination of conditions that occur together dramatically increases the risk of heart disease, stroke, and type 2 diabetes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Co-financing value: PLN 26,999,202.96<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>The total cost of the project: PLN 49,940,290.61<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>FGF1 analogue: a new therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases<\/p>\n","protected":false},"author":30,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53],"tags":[],"class_list":["post-29455","post","type-post","status-publish","format-standard","hentry","category-pl-co-financed-projects-implemented"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FAIND 2.0 - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/faind-2-0\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FAIND 2.0 - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"FGF1 analogue: a new therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/faind-2-0\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-09T09:27:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-09T12:13:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/02\/pasek-rna.jpg\" \/>\n<meta name=\"author\" content=\"Tomasz \u0141aguna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tomasz \u0141aguna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/faind-2-0\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/faind-2-0\\\/\"},\"author\":{\"name\":\"Tomasz \u0141aguna\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/2ec91b502f1ef5c36c61eca9cb11497b\"},\"headline\":\"FAIND 2.0\",\"datePublished\":\"2023-05-09T09:27:49+00:00\",\"dateModified\":\"2023-05-09T12:13:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/faind-2-0\\\/\"},\"wordCount\":146,\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/faind-2-0\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/pasek-rna.jpg\",\"articleSection\":[\"PL - co-financed projects implemented\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/faind-2-0\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/faind-2-0\\\/\",\"name\":\"FAIND 2.0 - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/faind-2-0\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/faind-2-0\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/pasek-rna.jpg\",\"datePublished\":\"2023-05-09T09:27:49+00:00\",\"dateModified\":\"2023-05-09T12:13:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/2ec91b502f1ef5c36c61eca9cb11497b\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/faind-2-0\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/faind-2-0\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/faind-2-0\\\/#primaryimage\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/pasek-rna.jpg\",\"contentUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/pasek-rna.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/faind-2-0\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FAIND 2.0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/2ec91b502f1ef5c36c61eca9cb11497b\",\"name\":\"Tomasz \u0141aguna\",\"sameAs\":[\"http:\\\/\\\/ontherocks.pl\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FAIND 2.0 - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/faind-2-0\/","og_locale":"en_US","og_type":"article","og_title":"FAIND 2.0 - Celon Pharma","og_description":"FGF1 analogue: a new therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases","og_url":"https:\/\/celonpharma.com\/en\/faind-2-0\/","og_site_name":"Celon Pharma","article_published_time":"2023-05-09T09:27:49+00:00","article_modified_time":"2023-05-09T12:13:39+00:00","og_image":[{"url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/02\/pasek-rna.jpg","type":"","width":"","height":""}],"author":"Tomasz \u0141aguna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tomasz \u0141aguna","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/faind-2-0\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/faind-2-0\/"},"author":{"name":"Tomasz \u0141aguna","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/2ec91b502f1ef5c36c61eca9cb11497b"},"headline":"FAIND 2.0","datePublished":"2023-05-09T09:27:49+00:00","dateModified":"2023-05-09T12:13:39+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/faind-2-0\/"},"wordCount":146,"image":{"@id":"https:\/\/celonpharma.com\/en\/faind-2-0\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/02\/pasek-rna.jpg","articleSection":["PL - co-financed projects implemented"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/faind-2-0\/","url":"https:\/\/celonpharma.com\/en\/faind-2-0\/","name":"FAIND 2.0 - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/celonpharma.com\/en\/faind-2-0\/#primaryimage"},"image":{"@id":"https:\/\/celonpharma.com\/en\/faind-2-0\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/02\/pasek-rna.jpg","datePublished":"2023-05-09T09:27:49+00:00","dateModified":"2023-05-09T12:13:39+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/2ec91b502f1ef5c36c61eca9cb11497b"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/faind-2-0\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/faind-2-0\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/celonpharma.com\/en\/faind-2-0\/#primaryimage","url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/02\/pasek-rna.jpg","contentUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/02\/pasek-rna.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/faind-2-0\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"FAIND 2.0"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/2ec91b502f1ef5c36c61eca9cb11497b","name":"Tomasz \u0141aguna","sameAs":["http:\/\/ontherocks.pl"]}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/29455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/30"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=29455"}],"version-history":[{"count":1,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/29455\/revisions"}],"predecessor-version":[{"id":29457,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/29455\/revisions\/29457"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=29455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=29455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=29455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}